Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Tax Provisions (2021 - 2022)

Cartesian Therapeutics (RNAC) has disclosed Tax Provisions for 2 consecutive years, with -$288000.0 as the latest value for Q4 2022.

  • Quarterly Tax Provisions fell 308.7% to -$288000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $15.4 million through Dec 2022, down 3.81% year-over-year, with the annual reading at -$9.2 million for FY2025, 3164.33% down from the prior year.
  • Tax Provisions for Q4 2022 was -$288000.0 at Cartesian Therapeutics, up from -$321000.0 in the prior quarter.
  • The five-year high for Tax Provisions was $15.8 million in Q3 2021, with the low at -$321000.0 in Q3 2022.